Myriad myRisk® Hereditary Cancer Article in Journal of Clinical Oncology Highlights Importance of Expanding Genetic Testing ...
March 30 2016 - 7:05AM
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular
diagnostics and personalized medicine, working in collaboration
with researchers from the Harvard Medical School, today announced
that the Journal of Clinical Oncology has published a paper showing
the frequency of germline mutations in 25 cancer susceptibility
genes among patients with breast cancer.
“This is the first study to show the frequency of germline
mutations in BRCA1/2 and other breast cancer predisposition genes
in a sequential series of breast cancer patients prospectively
collected and unselected for family history or age,” said
Anne-Renee Hartman, M.D., an author of the publication and senior
vice president of clinical development at Myriad Genetic
Laboratories. "Overall, the 25-gene panel identified 70
percent more breast cancer causing mutations than BRCA1/2 testing
alone. This important new finding is being used to identify
more patients with mutations with the ultimate goal of helping them
and their families to take appropriate risk reduction
measures."
In this study, 488 patients newly diagnosed with breast cancer
at the Dana-Farber Cancer Institute were evaluated for mutations in
25 cancer genes using the Myriad myRisk® Hereditary Cancer
test. The results show that 52 patients, or 10 percent, had a
germline mutation in a breast cancer predisposition gene.
Approximately 30 mutations were in BRCA1/2 genes and 21 were
in other cancer genes, representing a 70 percent increase in
mutations identified above BRCA testing alone. Importantly,
of the women with deleterious mutations 22, or 42 percent, were
diagnosed after age 45, suggesting that older patients may benefit
from genetic testing using the 25-gene panel.
“We are delighted to have partnered with Myriad to examine this
important question,” said Judy E. Garber, M.D., director,
Center for Cancer Genetics and Prevention, Dana-Farber Cancer
Institute, and one of the lead investigators in the study.
“It is clear that panel testing is providing new information on
inherited breast cancer predisposition, and we hope this study
provides another piece of the puzzle.”
The online JCO publication can be accessed at:
http://bit.ly/1Z6rLEj. Follow Myriad on Twitter via @MyriadGenetics
to stay informed about news and updates from the Company.
About Myriad myRisk® Hereditary Cancer
TestingThe Myriad myRisk Hereditary Cancer test uses an
extensive number of sophisticated technologies and proprietary
algorithms in an 850 step laboratory process to evaluate 25
clinically significant genes associated with eight hereditary
cancer sites including: breast, colon, ovarian, endometrial,
pancreatic, prostate and gastric cancers and melanoma. For
more information visit:
https://www.myriad.com/products-services/hereditary-cancers/myrisk-hereditary-cancer/.
About Myriad GeneticsMyriad Genetics Inc., is a
leading personalized medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on
three strategic imperatives: transitioning and expanding its
hereditary cancer testing markets, diversifying its product
portfolio through the introduction of new products and increasing
the revenue contribution from international markets. For more
information on how Myriad is making a difference, please visit the
Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer,
myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx,
myChoice HRD, Vectra and Prolaris are trademarks or registered
trademarks of Myriad Genetics, Inc. or its wholly owned
subsidiaries in the United States and foreign countries. MYGN-F,
MYGN-G
Safe Harbor StatementThis press release
contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements related to the clinical utility of the Myriad myRisk®
Hereditary cancer gene panel test; multi-gene panel testing with
Myriad myRisk Hereditary Cancer providing clinically significant
results that drive appropriate changes in patient care; new data
demonstrating positive perceptions from patients after they receive
a multi-gene test result; the ability of the myRisk Hereditary
Cancer test to identify a subset of patients with deleterious
mutations who historically would have been missed by traditional
genetic testing for BRCA1/2 genes alone, and who could receive
appropriate medical management as a result; the findings of the
studies suggesting that patients diagnosed with breast cancer at
older ages may benefit from genetic testing with the Myriad myRisk
Hereditary Cancer gene panel test; the Company’s commitment to
bringing transformative molecular diagnostics to people with
cancer; and the Company's strategic directives under the
caption "About Myriad Genetics." These "forward-looking
statements" are based on management's current expectations of
future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially
and adversely from those set forth in or implied by forward-looking
statements. These risks and uncertainties include, but are not
limited to: the risk that sales and profit margins of our molecular
diagnostic tests and pharmaceutical and clinical services may
decline; risks related to our ability to transition from our
existing product portfolio to our new tests, including unexpected
costs and delays; risks related to decisions or changes in
governmental or private insurers’ reimbursement levels for our
tests or our ability to obtain reimbursement for our new tests at
comparable levels to our existing tests; risks related to increased
competition and the development of new competing tests and
services; the risk that we may be unable to develop or achieve
commercial success for additional molecular diagnostic tests and
pharmaceutical and clinical services in a timely manner, or at all;
the risk that we may not successfully develop new markets for our
molecular diagnostic tests and pharmaceutical and clinical
services, including our ability to successfully generate revenue
outside the United States; the risk that licenses to the technology
underlying our molecular diagnostic tests and pharmaceutical and
clinical services and any future tests and services are terminated
or cannot be maintained on satisfactory terms; risks related to
delays or other problems with operating our laboratory testing
facilities and our healthcare clinic; risks related to public
concern over genetic testing in general or our tests in particular;
risks related to regulatory requirements or enforcement in the
United States and foreign countries and changes in the structure of
the healthcare system or healthcare payment systems; risks related
to our ability to obtain new corporate collaborations or licenses
and acquire new technologies or businesses on satisfactory terms,
if at all; risks related to our ability to successfully integrate
and derive benefits from any technologies or businesses that we
license or acquire; risks related to our projections about our
business, results of operations and financial condition; risks
related to the potential market opportunity for our products and
services; the risk that we or our licensors may be unable to
protect or that third parties will infringe the proprietary
technologies underlying our tests; the risk of patent-infringement
claims or challenges to the validity of our patents or other
intellectual property; risks related to changes in intellectual
property laws covering our molecular diagnostic tests and
pharmaceutical and clinical services and patents or enforcement in
the United States and foreign countries, such as the Supreme Court
decision in the lawsuit brought against us by the Association for
Molecular Pathology et al; risks of new, changing and competitive
technologies and regulations in the United States and
internationally; and other factors discussed under the heading
"Risk Factors" contained in Item 1A of our most recent Annual
Report on Form 10-K for the fiscal year ended June 30, 2015, which
has been filed with the Securities and Exchange Commission, as well
as any updates to those risk factors filed from time to time in our
Quarterly Reports on Form 10-Q or Current Reports on Form
8-K. All information in this press release is as of the date
of the release, and Myriad undertakes no duty to update this
information unless required by law.
Media Contact: Ron Rogers
(908) 285-0248
rrogers@myriad.com
Investor Contact: Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Sep 2023 to Sep 2024